Guangzhou Lbp Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
April 13, 2021 at 02:00 pm IST
Share
Guangzhou LBP Medicine Science & Technology Co., Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 375.433 million compared to CNY 355.159 million a year ago. Operating income was CNY 100.196 million compared to CNY 88.796 million a year ago. Net income was CNY 84.745 million compared to CNY 73.988 million a year ago. Basic earnings per share from continuing operations was CNY 1.09 compared to CNY 1.06 a year ago.
Guangzhou LBP Medicine Science & Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments. The Companyâs main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The Company operates its businesses within the domestic market and to overseas markets.